Compared to Estimates, Amgen (AMGN) Q4 Earnings: A Look at Key Metrics

Amgen (AMGN) reported $9.09 billion in revenue for the quarter ended December 2024, representing a year-over-year increase of 10.9%. EPS of $5.31 for the same period compares to $4.71 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $8.86 billion, representing a surprise of +2.54%. The company delivered an EPS surprise of +5.57%, with the consensus EPS estimate being $5.03.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.Here is how Amgen performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Product Sales- EPOGEN- U.S. $19 million versus $34.61 million estimated by eight analysts on average. Compared to the year-ago quarter, this number represents a -65.5% change. Product Sales- Neulasta- U.S. $72 million versus the seven-analyst average estimate of $106.76 million. The reported number represents a year-over-year change of -65.4%. Product Sales- Neulasta- ROW: $26 million compared to the $24.37 million average estimate based on seven analysts. The reported number represents a change of -16.1% year over year. Product Sales- Otezla- U.S. $514 million versus $499.93 million estimated by six analysts on average. Compared to the year-ago quarter, this number represents a -2.3% change. Product Sales- BLINCYTO- Total: $381 million compared to the $341.94 million average estimate based on 10 analysts. The reported number represents a change of +58.1% year over year. Product Sales- Repatha- Total: $606 million compared to the $555.05 million average estimate based on 10 analysts. The reported number represents a change of +45.3% year over year. Product Sales- KYPROLIS- Total: $372 million versus the 10-analyst average estimate of $385.99 million. Product Sales- Vectibix- Total: $246 million versus $274 million estimated by 10 analysts on average. Product Sales- Enbrel- Total: $1.02 billion versus the 10-analyst average estimate of $863.80 million. Revenue- Other revenues: $370 million versus $377.86 million estimated by 10 analysts on average. Compared to the year-ago quarter, this number represents a +1.9% change. Product Sales- Neulasta- Total: $98 million versus the 10-analyst average estimate of $121.89 million. The reported number represents a year-over-year change of -59%. Revenue- Product sales: $8.72 billion versus the 10-analyst average estimate of $8.48 billion. The reported number represents a year-over-year change of +11.3%. View all Key Company Metrics for Amgen here>>>Shares of Amgen have returned +11.7% over the past month versus the Zacks S&P 500 composite's +1% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.Research Chief Names "Single Best Pick to Double"From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Amgen Inc. (AMGN): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks